BCL2 and diffuse large B-cell lymphoma: In DLBCL sublines that are selected for resistance to the BCL-2 inhibitors ABT-199/737, dual PI3K/mTOR or mTOR selective inhibitors strongly enhance the efficacy of BCL-2 antagonism [13, 14].